Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.
Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS.
Jacobsen E, et al. Among authors: freedman as.
Leuk Lymphoma. 2015 Apr;56(4):993-8. doi: 10.3109/10428194.2014.941835. Epub 2014 Aug 20.
Leuk Lymphoma. 2015.
PMID: 25012943
Clinical Trial.